Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
BACKGROUND
Despite their efficacy in the treatment of benign prostatic hyperplasia (BPH) the popularity of inhibitors of 5α-reductase (5ARI) is limited by their association with adverse sexual side effects. However, the real impact of 5ARI on sex hormones and sexual function is controversial.


OBJECTIVE
To investigate the role of 5ARI therapy on hormonal parameters and sexual function in men already complaining of sexual problems.


METHODS
A consecutive series of 3837 men (mean age 63.5±12.8 yr) attending our outpatient clinic for sexual dysfunction was retrospectively studied. Several clinical, biochemical, and instrumental (penile color doppler ultrasound) factors were evaluated.


RESULTS
Among the patients studied, 78.7% reported erectile dysfunction, 51.1% hypoactive sexual desire (HSD), 86.7% perceived reduced sleep-related erections (PR-SRE) and 19.1% premature ejaculation. The use of 5ARI was associated with an increased risk of HSD and PR-SR whereas no relationship was found with erectile dysfunction and ejaculation disturbances. Subjects using 5ARI also more frequently had gynecomastia along with reduced SHBG and higher calculated free testosterone levels. All these associations were confirmed in a case-control study comparing 5ARI users with age-body mass index-smoking status and total testosterone-matched controls.


CONCLUSIONS
Our data indicates that use of 5ARI in men with sexual dysfunction does not significantly exacerbate pre-existing ejaculatory or erectile difficulties, but can further impair their sexual life by reducing sexual drive and spontaneous erection.
Sexual Medicine and Andrology Unit, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy.
G
G
Corona
G
G
Rastrelli
E
E
Maseroli
G
G
Balercia
A
A
Sforza
G
G
Forti
E
E
Mannucci
M
M
Maggi
D058891:5-alpha Reductase Inhibitors / Q000009:adverse effects*; D000368:Aged; D001378:Azasteroids / Q000009:adverse effects*; D016022:Case-Control Studies; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors / Q000378:metabolism; D000068538:Dutasteride; D004542:Ejaculation / Q000187:drug effects; D007172:Erectile Dysfunction / Q000139:chemically induced*; D018120:Finasteride / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D012725:Sexual Behavior / Q000187:drug effects; D012735:Sexual Dysfunction, Physiological / Q000150:complications / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000139:chemically induced*; D013739:Testosterone / Q000097:blood
D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D013739:Testosterone; D018120:Finasteride; D042944:Cholestenone 5 alpha-Reductase; D000068538:Dutasteride